New light therapy could fade Port-Wine stains
NCT ID NCT05171894
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment called Hemoporfin photodynamic therapy for port-wine birthmarks. It involves injecting a drug that is activated by green light to target the birthmark. 84 adults aged 18 to 75 will receive up to 3 treatment cycles to see which light dose works best and is safest.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hemoporfin (a photosensitizing drug) plus green light
- What this could lead to
- If successful, this could offer a more effective treatment for port-wine birthmarks, potentially reducing their appearance with fewer sessions.
- What could go wrong
- This is an early Phase 2 trial with only 84 participants, so results may not apply to everyone. Side effects from the drug and light are possible, and the treatment may not work for all birthmark locations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEVUS FLAMMEUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Cosmetic Associates of La Jolla, Inc. d/b/a West Dermatology Research Center
RECRUITINGSan Diego, California, 92121, United States
-
Maryland Dermatology, Laser, Skin & Vein Institute
RECRUITINGHunt Valley, Maryland, 21030, United States
-
Miami Dermatology and Laser Institute
RECRUITINGMiami, Florida, 33173, United States
-
St. Luke's University Health Network
RECRUITINGBethlehem, Pennsylvania, 18015, United States
-
UCI Health Beckman Laser Institute & Medical Clinic
RECRUITINGIrvine, California, 92697, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.